Human oral mucosa stem cells (hOMSC) are a recently described neural crest-derived stem cell population. Therapeutic quantities of potent hOMSC can be generated from small biopsies obtained by minimally invasive procedures. Our objective was to evaluate the potential of hOMSC to differentiate into astrocyte-like cells and provide peripheral neuroprotection. We induced hOMSC differentiation into cells showing an astrocyte-like morphology that expressed characteristic astrocyte markers as glial fibrillary acidic protein, S100\(\beta\), and the excitatory amino acid transporter 1 and secreted neurotrophic factors (NTF) such as brain-derived neurotrophic factor, vascular endothelial growth factor, glial cell line-derived neurotrophic factor, and insulin-like growth factor 1. Conditioned medium of the induced cells rescued motor neurons from hypoxia or oxidative stress in vitro, suggesting a neuroprotective effect mediated by soluble factors. Given the neuronal support (NS) ability of the cells, the differentiated cells were termed hOMSC-NS. Rats subjected to sciatic nerve injury and transplanted with hOMSC-NS showed improved motor function after transplantation. At the graft site we found the transplanted cells, increased levels of NTF, and a significant preservation of functional neuromuscular junctions, as evidenced by colocalization of \(\alpha\)-bungarotoxin and synaptophysin. Our findings show for the first time that hOMSC-NS generated from oral mucosa exhibit neuroprotective effects in vitro and in vivo and point to their future therapeutic use in neural disorders.

**Key Words.** Oral mucosa stem cells • Astrocytes • Cell therapy • Neural differentiation

**ABSTRACT**

Human oral mucosa stem cells (hOMSC) are a recently described neural crest-derived stem cell population. Therapeutic quantities of potent hOMSC can be generated from small biopsies obtained by minimally invasive procedures. Our objective was to evaluate the potential of hOMSC to differentiate into astrocyte-like cells and provide peripheral neuroprotection. We induced hOMSC differentiation into cells showing an astrocyte-like morphology that expressed characteristic astrocyte markers as glial fibrillary acidic protein, S100\(\beta\), and the excitatory amino acid transporter 1 and secreted neurotrophic factors (NTF) such as brain-derived neurotrophic factor, vascular endothelial growth factor, glial cell line-derived neurotrophic factor, and insulin-like growth factor 1. Conditioned medium of the induced cells rescued motor neurons from hypoxia or oxidative stress in vitro, suggesting a neuroprotective effect mediated by soluble factors. Given the neuronal support (NS) ability of the cells, the differentiated cells were termed hOMSC-NS. Rats subjected to sciatic nerve injury and transplanted with hOMSC-NS showed improved motor function after transplantation. At the graft site we found the transplanted cells, increased levels of NTF, and a significant preservation of functional neuromuscular junctions, as evidenced by colocalization of \(\alpha\)-bungarotoxin and synaptophysin. Our findings show for the first time that hOMSC-NS generated from oral mucosa exhibit neuroprotective effects in vitro and in vivo and point to their future therapeutic use in neural disorders.

**INTRODUCTION**

Stem cell-based therapy offers promise for future treatment of various neurodegenerative diseases. Two main potential approaches are currently under research. One strategy is cell replacement aimed to substitute lost cells with new cells, as in the case of Parkinson’s disease in which lost dopaminergic neurons are replaced with new dopamine-secreting cells [1]. The second approach is to use the cells as vectors that produce and secrete neuroprotective agents or neurotrophic factors (NTF) to provide neuroprotection or trophic stimuli to the surviving neurons. In the nervous system, astrocytes, also called astrogia, play a major neuroprotective role [2]. Recently, malfunction of astrocytes has been proposed to play a role in the pathogenesis of noncell autonomous diseases [3–6]. Recent evidence indicates that NTF-secreting astrocytes support neuronal functional recovery from injuries [2, 7–13].

NTF are naturally occurring polypeptides that support the development, survival, and neurite outgrowth in neurons [14]. Several studies concerning neuronal injury have demonstrated that NTF such as brain-derived neurotrophic factor (BDNF), vascular endothelial growth factor (VEGF), glial cell line-derived neurotrophic factor (GDNF) and insulin-like growth factor 1 (IGF-1) play an important role in the development, maintenance, and regeneration of the nervous system [7, 15–22]. NTF administration in neuronal dysfunction animal models has been related to axon regeneration and functional recovery [22–25]. Although there are some indications of restoration and recovery of motor function, clinical trials of systemic or intrathecal administration of recombinant NTF to patients with motor neuron disorders did not show significant efficacy, probably due to NTF short half-life, poor delivery, and low concentrations at target sites [26, 27]. Thus, a continuous cellular-derived supply of NTF may overcome this drawback and provide an efficient treatment modality. Our group has previously shown that after a two-step medium-based protocol and without transgenic expression, mesenchymal stem cells can be induced into NTF-secreting cells with astrocyte-like characteristics [18]. After transplantation of these cells, clinical symptoms of multiple sclerosis, Parkinson’s disease, Huntington, optic nerve transection, and sciatic nerve injury animal models were significantly attenuated [15, 19, 28–31]. Our
data demonstrated that these cells increased NTF levels at the injury site and provided an environment that nursed the damaged neuronal tissue.

We recently described a new stem cell population isolated from the neural crest-derived lamina proppa of the oral mucosa [32]. This population, termed human oral mucosa-derived stem cells (hOMSC), expresses a primitive neural crest (NC) stem cell phenotype, as evidenced by the expression of the pluripotency transcription factors Oct4, Nanog, and Sox2 and the constitutive expression of the NC markers nestin, Snail, and p75 and the neuronal marker β-III tubulin.

The embryonic NC gives rise to different glial population of the peripheral nervous system (PNS) such as glial satellite cells of the ganglia, enteric glia, and myelinating and nonmyelinating Schwann cells [33]. The task of these glial cells is to provide support to the neuronal cells of the PNS [33, 34]. Moreover, this plasticity is retained postnatal by some differentiated NC-derived cells [34–36]. hOMSC are highly clonogenic and possess the ability to differentiate into NC-derived cell lineages and tissues in vitro and in vivo [32, 36]. Given the multipotency of hOMSC, their NC-related origin, and the fact that during development NC cells gives rise to glial cells, we hypothesized that these cells under the appropriate signaling by soluble factors could serve as a useful stem cell source for autologous cell therapy of neurological disorders. In the present study, we show that hOMSC can acquire an astrocyte-like phenotype characterized by the upregulation of astrocyte markers, enhanced NTF synthesis, and secretion, and consequently by its capability to rescue motor neurons from toxic stimuli in vitro. Most importantly, these cells show the ability to significantly increase the motor performance after sciatic nerve injury in rats and preserve their functional neuromuscular junctions.

**Materials and Methods**

**hOMSC Culture**

hOMSC were obtained from oral mucosa biopsies performed during routine oral surgical procedures after receiving informed consent from the donors and the approval of the institutional Helsinki Committee at the Baruch Padeh Medical Center (Poria, Israel). hOMSC were generated and expanded in medium consisting of low-glucose Dulbecco’s modified Eagle’s medium supplemented with 100 mg/ml streptomycin, 100 U/ml penicillin, 1250 U/ml Nystatin (SPN) (Biological Industries, Beit-Haemek, Israel, http://www.bioind.com), 2 mM glutamine (Invitrogen, Carlsbad, CA, http://www.invitrogen.com), and 10% fetal calf serum (Gibco, Grand Island, NY, http://www.invitrogen.com), as described by Marynka-Kalmani et al. [32]. Briefly, biopsies were incubated at 4°C overnight in dispase (Sigma-Aldrich, Rehovot, Israel, http://www.sigmaaldrich.com). Then the epithelial layer was separated from the lamina propria, and the latter was minced into pieces approximately 0.5 mm³. The pieces were placed on the floor of 35-mm culture dishes (Nunc, Rochester, NY, http://www.nuncbrand.com). The above-mentioned expansion medium was added gently to the explants to allow their attachment to the floor of the dish. Cells that emigrated from the explant to the culture dishes were harvested with 0.25% trypsin (Biological Industries, Beit-Haemek, Israel) and seeded at a cell density of 4 × 10⁴ cells per cm². Cells were passaged at 70%–80% confluence. hOMSC at passages 4–20 were used in the experiments described below.

**hOMSC Differentiation**

A two-step medium-based differentiation protocol was performed. In the first step, the cells were incubated in serum-free conditions [Dulbecco’s modified Eagle’s medium [DMEM] low glucose/SPN/glutamine) with the addition of N2 supplement (Gibco), basic fibroblast growth factor 2 (R&D Systems, Minneapolis, MN, http://www.rndsystems.com), and epidermal growth factor (EGF; R&D Systems), all of these supplements at a final concentration of 20 ng/ml. Following 72 hours, the second differentiation step was initiated. Cells were incubated in serum-free medium (DMEM low glucose/SPN/glutamine) with the addition of 1 mM dibutyryl cyclic AMP (Sigma-Aldrich), 0.5 mM 3-isobutyl-1-methylxanthine (IBMX) (Sigma-Aldrich), 50 ng/ml Neuregulin, and 1 ng/ml platelet-derived growth factor (PDGF; Peprotech Asia, Rehovot, Israel, http://www.peprotech.com) for an additional 72 hours. For conditioned medium experiments, medium was replaced with serum-free medium after the end of the differentiation protocol and cells were incubated for another 48 hours. Resultant medium was centrifuged to remove cells and debris, and protease inhibitor was added and stored at −80°C until used.

**Immunodetection**

For immunofluorescence analysis, cells were fixed in 4% paraformaldehyde in phosphate-buffered saline (PBS) and preincubated for 60 minutes in blocking solution (5% goat serum, 1% bovine serum albumin, 0.05% Triton X-100 PBS). Primary antibodies were diluted in the blocking solution and applied overnight at 4°C. Primary antibodies were incubated in blocking solution overnight at 4°C. The following antibodies were used: glial fibrillary acidic protein (GFAP) (1:200; Dako, Glostrup, Denmark, http://www.dako.com), S100β (1:200; Sigma-Aldrich), BDNF (1:100; Santa Cruz Biotechnology, Santa Cruz, CA, http://www.scbt.com), GDNF (1:100; Santa Cruz Biotechnology), IGF-1 (Santa Cruz Biotechnology), and VEGF (Santa Cruz Biotechnology). Primary antibodies were detected with fluorescently labeled secondary antibodies Alexa 488 and 568 (1:500; Molecular Probes, Eugene, OR, http://probes.invitrogen.com) for 1 hour at room temperature. Nuclear DNA was stained using 4′,6-diamidino-2-phenylindole (DAPI) (1:1,000; Sigma-Aldrich). Cells incubated overnight with the blocking solution and then only with the secondary antibodies served as negative controls and for determining the photography exposure settings. Photographs were taken with fluorescence Olympus IX70 SFX2 microscope with a fluorescent light source (excitation wavelength, 330–385 nm; barrier filter, 420 nm) and a U-MNU filter cube (Olympus, Center Valley, PA, http://www.olympusamerica.com). Fluorescence quantification was performed by integrated density of fluorescence by ImageJ software (National Institutes of Health, Bethesda, MD, http://imagej.nih.gov/ij/).

**Western Blot Analysis**

For Western blot analysis, cells were lysed in buffer containing PBS, 1% SDS, and complete protease inhibitor (Sigma-Aldrich), and loaded into 12% SDS-polyacrylamide gel electrophoresis. Three independent cultures were used as biological replicates. Gels were transferred using liquid transference (300 mA, 1.15hs), and membranes were blocked with PBS buffer/5% milk for 2 hours at room temperature. The membranes were probed with the following antibodies: GFAP (1:500; Invitrogen, Carlsbad, CA), excitatory amino acid transporter 1 (EAAT1) (1:750; Abcam, Cambridge,
U.K., http://www.abcam.com), and β-actin (1:1,000; Sigma-Aldrich), and followed by IRDye (680, 800 nm)-conjugated secondary antibody (LI-COR, Lincoln, NE). The membranes were analyzed, and bands were quantified with Odyssey IR imaging systems (LI-COR).

**Real-Time Polymerase Chain Reaction**

Total RNA was isolated by TRI reagent (Invitrogen), according to the supplier’s recommendations. The amount and quality of RNA were determined with the ND-1000 spectrophotometer (NanoDrop, Wilmington, DE, http://www.nanodrop.com). For each sample, 2 μg RNA was used for reverse transcription performed with random primers and SuperScript III (Invitrogen). Real-time semi-quantitative polymerase chain reaction (PCR) of the desired genes was performed in an ABI Prism 7700 sequence detection system (Applied Biosystems, Foster City, CA, http://www.appliedbiosystems.com) by using PlatinumR SYBR Green qPCR SuperMix UDG with ROX (Invitrogen). PCR amplification was set at 40 cycles (program: 2 minutes at 50°C; 2 minutes at 95°C; 40 repeats of 15 seconds at 95°C and 30 seconds at 60°C). Data were quantified by using the ∆∆ cycle threshold method and averaged upon normalization to the glyceraldehyde-3-phosphate dehydrogenase gene. The following primers (IDT, Jerusalem, Israel) were used: lactate dehydrogenase A, 5'-CATGAGACTGGTA (forward) and 5’-ATCTTGACCTACGTGGCTTGGA-3’ (reverse); VEGF, 5’-TACCTCCACATGCCAACAGT-3’ (forward) and 5’-GATGATCTGCTCCTCCTCTT-3’ (reverse); BDNF, 5’-AGCTCCGGTTGATACCTGG-3’ (forward) and 5’-CCCTGGTGGAACTTCTTTGCG-3’ (reverse); α–TACCTCCACATGCCAACAGT-3’ (forward) and 5’-GATGATCTGCTCCTCCTCTT-3’ (reverse); NF-κB, 5’-CGTATTCCGACGAGGCCAACC-3’ (forward) and 5’-CCAAGGCCCCAACAACAGC-3’ (reverse); β–tubulin, 5’-CTCAGGGGCTTCTGGAGAC-3’ (forward) and 5’-AGGCTGCTGCCATTTTAC-3’ (reverse); neural adhesion molecule (NCAM), 5’-AACCACCTACGATCCTCGCC-3’ (forward) and 5’-CTTGAATACGGCTGTTG-3’ (reverse); octamer-binding transcription factor 4 (OCT-4), 5’-CTCCCTCTCCACATTGCCCAAC-3’ (forward) and 5’-GACAGGGGGAGGGGAGGAGTCTAGG-3’ (reverse); NANOG, 5’-TG CCTCAGACGAGACGTCT-3’ (forward) and 5’-AGTGGTTTGGCTTGG-3’ (reverse).

**Enzyme-Linked Immunosorbent Assay-Based Measurement of NTF Secretion**

At the end of the differentiation process, human VEGF and BDNF concentrations in the cell culture supernatant were measured using a sandwich enzyme-linked immunosorbent assay (ELISA) procedure, according to the manufacturer’s instructions (DuoSet; R&D Systems). Medium was processed as conditioned medium (as described above). Briefly, supernatant media samples (100 μl) were measured in triplicate per flask. The samples were incubated overnight on coated plates, followed by exposure to a second antibody and streptavidin-horseradish peroxidase-based detection (H2O2 and tetramethylbenzidine solution). After the addition of the kit stop solution, the absorbance at 450 nm and 570 nm was recorded using a microplate reader. The results (mean ± SEM) were calculated as secreted protein by 1 million cells per milliliter of medium.

**Cell Viability Assay**

We have tested the ability of undifferentiated and differentiated hOMSC conditioned media prepared as described above to protect mouse motor neuron-like hybrid cell line (NSC-34) from hypoxia (2% O2, 5% CO2, 93% N2) and oxidative stress (25 μM H2O2). NSC-34 were plated in 96-well plates at 10,000 cells per well and placed in a hypoxic environment for 72 hours in a chamber together with the respective conditioned media. After 72 hours, Alamar blue 10% (AbD Serotec, Kidlington, U.K., http://www.ab-direct.com) was added to the cells to quantify viability. The assay was conducted in triplicate, and results were read at wavelengths of 590 nm using a FLUOstar device (BMG Labtech, Offenburg, Germany, http://www.bmglabtech.com). Results were normalized to cells under the same treatments in normoxia. For oxidative stress studies, NSC-34 cells were exposed to 25 μM hydrogen peroxide (Sigma-Aldrich) and incubated with conditioned media of undifferentiated and differentiated hOMSC for 24 hours. Data were normalized and expressed as percentage of cells present in serum-free conditions with no insult.

**Sciatic Nerve Injury and Cell Transplantation**

The sciatic nerve crush model was applied on 8-week-old male Sprague-Dawley rats (n = 24; Harlan, Jerusalem, Israel, http://www.harlan.com), weighing 230–250 g. Rats were housed under 12-hour-light/12-hour-dark conditions and grown in individually ventilated cages with ad libitum access to food and water. All experimental protocols were approved by the Tel Aviv University Committee of Animal Use for Research and Education. Every effort was made to reduce the number of animals used and to minimize their suffering. Two independent experiments of four animals per group were performed. hOMSC derived from a different donor were used in each independent experiment. The results from the two experiments were pooled and presented as the mean ± SEM/animal. Rats were anesthetized for the sciatic nerve injury and for cell transplantation with chloral hydrate (300 mg/kg; Sigma-Aldrich), and subcutaneous daily cyclosporine (Novartis International, Basel, Switzerland, http://www.novartis.com) was given (3.75 mg per rat). The right sciatic nerve was exposed, and a vessel clamp was applied 10 mm above the first branching of the nerve, for 30 seconds. Then the muscle and skin were closed in layers. Twenty-four hours after injury, differentiated hOMSC and naive cells were harvested, labeled with superparamagnetic iron oxide (5 g/ml; Feridex; Bayer HealthCare, Leverkusen, Germany, http://www.bayer.com), centrifuged, resuspended at a concentration of 1 × 10⁶ cells per 100 μl of saline, and maintained on ice until transplantation. A total of 24 animals was subjected to sciatic nerve injury and then divided into three groups of 8 animals each. Each group was treated with either differentiated hOMSC or naive hOMSC or saline (control). A total of 100 μl of cell suspension (1 × 10⁶ cells) or saline was injected through the gastrocnemius muscle into the nerve surroundings and above the first branching of the nerve. To ascertain 98% viability of the cells to be transplanted, trypan blue staining was performed in parallel aliquots obtained from the same cultures from which the cells to be transplanted were obtained. All treated animals were sacrificed 10 days after transplantation for histological examination.

**Rat Motor Function Measurements**

Motor activity was measured using the San Diego Instrument test, Rotarod (San Diego Instruments, San Diego, CA, http://www.sandiegoinstruments.com), between days 1 and 10 after cell transplantation. This test measured the time that the rats remained on a rotating rod in accelerated speed (0–25 rpm). Following a brief training period, adult Sprague-Dawley rats were able to remain balanced on...
the rod for up to 4 minutes. After sciatic nerve crush, the rat’s ability to balance is severely compromised, causing the animal to fall off the rod after shorter periods of time. The average time measured in three consecutive runs for each rat was recorded, and the group’s performance was compared. The machine has a laser beam that detects the fall. The rotarod test was assessed at days −1, 0, 2, 4, 6, and 10 after transplantation. Data are presented as percentage values of each individual (mean [%] ± SEM) relative to the initial time they spent on the rod before injury.

Assessment of Cell Engraftment, Migration, and Phenotype Maintenance

To analyze cell survival following transplantation, hOMSC were infected with lentiviral particles (Gateway; Invitrogen) carrying the pLenti CMV-GFP-Puro plasmid (Addgene 17448, kindly deposited by Eric Campeau) and selected for puromycin resistance (2 μg/ml) for 2 weeks. Selected colonies were expanded and submitted to the differentiation protocol described above or maintained in expansion medium. Naïve and differentiated green fluorescent protein (GFP)+ cells were transplanted following sciatic nerve injury in 12 animals, as described above, each type of cell in a group of 6 animals. Three animals from each group were sacrificed 4 hours after transplantation. The remaining six animals treated with GFP+ cells and the animals used for motor tests were sacrificed 10 days after transplantation with CO2. The hind limb muscles were removed and frozen in liquid nitrogen. Muscles were sectioned perpendicularly to the long axis of the muscle. Serial sections of 30 μm were obtained using a cryostat (Leica CM1850) and placed on glass slides for histological and immunohistochemistry staining. Tissue sections of animals that did not receive cells were used as negative controls and for determining the photography exposure settings.

For determining cell engraftment and migration, the number of DAPI/GFP-positive cells was determined along a distance of 1280 (640 μm in each of the rostral and caudal directions from the transplantation site) at 4 hours and 10 days post-transplantation. Photographs were taken with a fluorescence Olympus IX70-S8F2 microscope with a fluorescent light source (excitation wavelength, 330–385 nm; barrier filter, 420 nm) and a U-MNU filter cube (Olympus).

Assessment of Neuromuscular Junction Innervations

Hind limb muscles were dissected and frozen in liquid nitrogen. Muscles were sectioned at 30 μm using a cryostat and placed on glass slides for staining. Sections (n = 10 per animal) were fixed with 4% paraformaldehyde-PBS and labeled with α-bungarotoxin conjugated with fluorescence marker Alexa Fluor 594 (1:500; Invitrogen) and anti-synaptophysin (rabbit polyclonal, 1:500; Santa Cruz Biotechnology) antibodies overnight at 4°C. After washing with PBS, the sections were incubated with anti-rabbit Alexa Fluor 488-conjugated antibody (1:1,000; Invitrogen) for 1 hour at room temperature, followed by washes, and covered with cover glasses using aqueous mounting medium (Invitrogen). Cells incubated overnight with the blocking solution and then only with the secondary antibodies served as negative controls and for determining the photography exposure settings. We classified neuromuscular junctions (NMJs) into two groups based on the degree of innervation of postsynaptic receptor plaques by nerve terminals. Endplates were scored as innervated if there was an overlap with the axon terminal, or denervated if the end plate was not associated with an axon.

Statistical Analysis

Results are expressed as mean ± SEM. All analyses were performed using SPSS version 19 software (SPSS Software, IBM Corp., Armonk, NY, http://www-01.ibm.com/software/analytics/spss/). Differences between two groups were statistically analyzed by t-test, whereas comparisons between three groups were analyzed by one-way analysis of variance (ANOVA). For the cell transplantation in vivo experiment, two-way ANOVA was performed. Tukey’s multiple comparison post hoc test was used to evidence specific differences between groups.

RESULTS

Differentiated hOMSC Show an Astrocyte-Like Phenotype

Following the two-step differentiation protocol, the entire culture of differentiated hOMSC underwent substantial morphological changes to a neural-like morphology, resembling that of astrocytes (Fig. 1). The observed morphological changes included cell condensation from an initial fusiform morphology to the formation of multiple projections emerging from the cell body. These changes correlate with an increase in the expression of classical astrocyte markers GFAP, S100β, and EAAT1 (GLAST) at the gene and protein levels, as evidenced by real-time PCR, immunofluorescence staining, and Western blots (Fig. 1). Moreover, differentiated hOMSC showed a significant reduction in the transcription levels of pluripotency markers OCT4 and NANOG (p < .05) and a moderate reduction in the neural crest marker p75NTR and the neuronal markers β-III tubulin and NCAM1 (p < .05) as compared with undifferentiated hOMSC (Fig. 1E). hOMSC differentiation into astrocyte-like cells resulted in enhanced expression of the neurotrophic factors BDNF, GDNF, IGF-1, and VEGF, as evidenced by immunofluorescence staining (Fig. 2). At mRNA level, VEGF and BDNF were also upregulated (p < .05) (Fig. 2A, 2B). VEGF and BDNF levels were substantially increased in the extracellular medium (p < .05), reaching concentrations of approximately 8 ng/ml per 106 cells and 1 ng/ml per 106 cells, respectively, as measured by ELISA (Fig. 2C, 2D).

Conditioned Medium of Differentiated hOMSC Protects Motor Neurons From Hypoxia and Oxidative Stress-Induced Cell Death In Vitro

To evaluate the potential of the differentiated cells to protect neuronal cultures from hypoxia and oxidative stress-induced cell death, the mouse motor neuron cell line NSC-34 [37] was used (Fig. 3). After 72 hours of hypoxia, cell viability in the untreated NSC-34 cultures and in NSC-34 treated with conditioned medium derived from naïve hOMSC decreased to 11.85% ± 0.82% and 15.23% ± 3.87% of the cell viability levels observed in NSC-34 cultures grown under normoxia (p < .05). In contrast, NSC-34 treated with conditioned medium from differentiated hOMSC cultures exhibited high survival rates (93.8% ± 9%) comparable to those of NSC-34 cultures maintained under normoxia conditions (p < .05) (Fig. 3A). The survival rate of NSC-34 cultures exposed to oxidative stress (25 μM H2O2) for 48 hours and treated with conditioned medium derived from differentiated hOMSC was similar to that of control cultures unexposed to oxidative stress.
stress. The survival rate of cultures treated with conditioned medium from naïve hOMSC and that of untreated cultures was 83.47% ± 6.8% and 65.88% ± 1.74%, respectively, of that of cultures unexposed to oxidative stress (p < .05) (Fig. 3B). Because of the neuroprotective capacity of the hOMSC-differentiated cells, they will be referred to in this work as hOMSC-derived neuron-supporting cells (hOMSC-NS).

hOMSC-NS Transplantation Increases Motor Performance After Sciatric Nerve Injury in Rats

The sciatic nerve injury model was used for testing the capacity of hOMSC-NS to support peripheral neural recovery (Fig. 4A). As demonstrated by the rotator test, a significant improvement in the motor function was achieved in the animals of the hOMSC-NS-transplanted group during the first stages of recovery, compared with that of animals treated with naïve hOMSC or saline (Fig. 4C). This improvement was statistically significant (p < .05) between days 1 and 7 after cell transplantation. No differences in the improvement of motor function were observed between the saline-treated and the naïve hOMSC-treated groups (p > .05).

Transplanted hOMSC-NS Preserved Neuromuscular Junctions After Injury

Ten days after the sciatic nerve crush, NMJs were evaluated and counted within the gastrocnemius and tibialis muscles in the crushed area in animals of the three groups (Fig. 7). Colocalization of the presynaptic protein synaptophysin (SYP) (red) and of the postsynaptic acetylcholine receptor ligand, α-bungarotoxin (α-BTX) (green), pointed to preserved and innervated NMJ (yellow) (Fig. 7A–7I). Staining for either α-BTX or SYP alone was considered as a denervated NMJ. Evaluation of the NMJ was

Ganz, Arie, Ben-Zur et al. 379

Figure 1. Differentiated human oral mucosa stem cells (hOMSC) exhibit an astrocyte-like phenotype. Bright field (A, B) and immunofluorescence microscopy (C, D) for S100β (red) and GFAP (green) of undifferentiated and differentiated hOMSC (scale bars = 100 μm). Decrease in the expression of pluripotency, neural crest, and neuronal markers and increase in the expression of the astrocytic markers GFAP and EAAT1 in differentiated hOMSC, as assessed by quantitative polymerase chain reaction (E). Confirmation of the increase observed in the astrocytic markers at the message level by quantitative Western blots (F). Abbreviations: DAPI, 4’,6-diamidino-2-phenylindole; Diff, differentiated; EAAT1, excitatory amino acid transporter 1; GFAP, glial fibrillary acidic protein; NANOG; NCAM, neural adhesion molecule; OCT4, octamer-binding transcription factor; Und, undifferentiated.
expressed as a percentage of preserved NMJ counts over total counted NMJ (α-BTX“+SY+” + α-BTX“+SY+”). We found that in gastrocnemius and tibialis muscles transplanted with hOMSC-NS, 89.4% ± 4.6% of the NMJs were innervated. In contrast, in muscles transplanted with hOMSC or saline only, 53.5% ± 8.3% and 48.2% ± 8% of the NMJs were innervated, respectively (Fig. 7J). Statistical analysis demonstrated significant difference between the hOMSC-NS-treated group and the other two groups, which did not differ from each other (ANOVA and Tukey’s post hoc analysis, p < .05).

Figure 2. Differentiated human oral mucosa stem cells present enhanced neurotrophic factors (NTF) production and secretion. (A): Immunofluorescence of intracellular NTF before and after differentiation, BDNF, GDNF, IGF-1, and VEGF (Aa–Ah). Scale bars = 100 μm. (B): VEGF and BDNF expression at the mRNA level (Ba, Bb) and secreted protein level (Bc, Bd) assessed by real-time PCR and enzyme-linked immunosorbent assay, respectively. Abbreviations: BDNF, brain-derived neurotrophic factor; GDNF, glial-derived neurotrophic factor; IGF-1, insulin-like growth factor 1; ND, not determined; PCR, polymerase chain reaction; VEGF, vascular endothelial growth factor.

Figure 3. Differentiated hOMSC-conditioned medium protects motor neurons from hypoxic (A) or oxidative (B) conditions. Treatments include serum-free medium and conditioned medium from differentiated and undifferentiated hOMSC. Data are presented as percentage (mean ± SEM) of cells without insult. Abbreviations: hOMSC, human oral mucosa stem cells; hOMSC-NS, human oral mucosa stem cells-neuronal support.

DISCUSSION

Stem cell therapy is evolving as a promising strategy for the treatment of degenerative and traumatic disorders of the central and peripheral nervous systems. To establish reproducible therapeutic protocols, similar to those accepted in drug therapy, therapeutic stem cell populations with a well-characterized phenotype must be developed and used. Allogeneic embryonic and fetal well-characterized stem cell lines are currently being tested in preclinical [40] and clinical settings [41, 42]. However,
immunologic, ethical, and safety issues still hamper their routine utilization. Autologous adult stem cells, derived from bone marrow [30, 43–45] or other sources [12, 46–48], have recently been coaxied by exposure to soluble factors or genetic manipulations to produce and secrete specific trophic factors with biologic activities. These cells have also been shown to ameliorate functional symptoms in animal models of trauma and neurodegenerative diseases [18, 28, 47–50]. However, the donor heterogeneity and aging may affect the outcome of the differentiation protocols and consequently the therapeutic efficacy of these stem cell populations [51–53]. In this respect, we have recently reported that hOMSC are a unique population of multipotent stem cells with a primitive NC-like phenotype [32]. hOMSC are localized within a specific niche in the NC-derived lamina propria of the adult and elderly oral mucosa. Moreover, hOMSC express low interdonor heterogeneity, and their growth, clonogenicity, and differentiation potentials are negligibly affected by aging [32].

The NC gives rise to a wide range of cell types, including neurons and glia of the PNS, melanocytes, craniofacial bones and cartilage, fibroblasts, smooth muscle cells, and endocrine cells [34]. Migrating NC cells are a heterogeneous collection of progenitors, including multipotent stem cells, cells with limited developmental potential, and fate-restricted precursors [34]. The influence of environmental signals is therefore crucial to ensure that postmigratory NC-derived cells express a defined phenotype corresponding to their position in the body. It was shown that the plasticity displayed by NC-derived cells is also retained postnatally by some differentiated cells. The idea of reprogramming NC phenotypes is supported by in vitro culture experiments that illustrate the ability of epidermal pigment cells and peripheral nerve Schwann cells, two differentiated NC-derived cells, isolated from quail embryos, to undergo reciprocal transdifferentiation [34, 35, 54].

Considering that the NC in development gives rise to neuronal supporting cells such as satellite glial cells of the ganglia or the...
enteric glia [33], and given the remarkable plasticity of NC-derived cells, we set out to test the propensity of this cell population to differentiate into glial cells with in vitro and in vivo neuroprotective capacity, mimicking astrocytes’ trophic and protective functions. It was demonstrated that neuregulin, or so-called heregulin, is involved in determination, proliferation, differentiation, and migration of glial cells in the developing brain, and also in promoting selective maturation and cell viability of astrocytes [55, 56]. PDGF also regulates astrocyte specification by the leukemia inhibitory factor and bone morphogenetic protein 2 pathways.

Figure 5. Transplanted cells survived 10 days after transplantation. GFP-labeled naive or differentiated hOMSC (A, B) (scale bar = 100 μm) were transplanted into rats with sciatic nerve injury (n = 6). Cell survival was evaluated 4 hours (t = 0) and 10 days (t = 10) after transplantation (C–F). Scale bars = 200 μm (C–F) and 50 μm (G). GFP+ cells were counted and graphed as number of cells per section (30 μm) along 1280 μm rostro-caudal consecutive sections (0 μm refers to the inoculation site) (H). Abbreviations: GFP, green fluorescent protein; hOMSC, human oral mucosa stem cells; hOMSC-NS, human oral mucosa stem cells-neuronal support.
Addition of fibroblast growth factor-2 (FGF-2) in vitro provides a permissive environment for the production of astrocytes from cortical progenitors via multiple mechanisms, including the ciliary neurotrophic factor signaling, which is a major astrogliogenic pathway. Injection of FGF-2 into the cerebral ventricles of embryos and genetic manipulation to eliminate FGF-2 resulted in increased and decreased glial populations, demonstrating that FGF-2 signaling pathways induce and regulate astrocyte specification.

In this study, we demonstrate that soluble factors, related to astrocyte differentiation, maturation, and increased NTF production, induced hOMSC homogenous differentiation into cells with induced upregulation of astrocyte markers, enhanced NTF secretion, and acquired neuroprotective capabilities.

The level of NTF secretion achieved after differentiation was comparable with those we published for myogenic cells transduced with viral vectors that effectively protected the sciatic nerve after injury. Moreover, VEGF secretion by hOMSC-NS was even higher than myogenic progenitors transduced to express this cytokine.

A major concern in cell therapy is the capacity of the differentiated cells in vitro to survive and maintain their phenotype following their transplantation in vivo. In the present work, we demonstrated that a considerable number of both cell types survived for at least 10 days, the critical period for neural regeneration in this model. Moreover, we could detect higher amounts of GFAP, VEGF, and BDNF in the muscle transplanted with hOMSC-NS compared with the other two groups. This observation correlated positively with motor and NMJ preservation. The findings that a higher expression of NTF was observed in hOMSC-NS-treated rats and that this secretion was colocalized with the astrocyte marker GFAP and also with cells of human origin point to the capacity of hOMSC-NS to maintain their astrocyte-like phenotype in vivo within the limit of the experimental period. We could not detect colocalization staining for GFAP and HuNu because of technical limitations.

The astrocyte-like phenotype of hOMSC-NS proved to have functional activity both in vitro and in vivo, as evidenced by their ability to rescue motor neurons subjected to chemical and respiratory stress, and by the ability to preserve NMJ innervation and enhance functional recovery of sciatic nerve-injured rats. The fact that this functional activity correlates with increased secretion of NTF by hOMSC strengthens previous observations that glial-like cells derived from extraneural adult tissues protect and support neuronal function via the continuous secretion of soluble NTF.

Oral mucosa is a readily accessible cell source. Biopsies as small as 4–3 × 3 mm generate under regular culture conditions trillions of hOMSC with a substantial propensity to differentiate into homogenous cultures of astrocyte-like cells. Preliminary results (data not shown) suggest that this propensity is negligibly affected by the age of the donor. Taken together, the data of the present and previous studies, showing that hOMSC are capable of developing into Schwann-like cells 2 months following their transplantation into severe combined immunodeficient mice, indicate that the oral mucosa might serve as an advantageous cell source for isolating therapeutic quantities of stem cells with functional activity.

Figure 6. hOMSC-NS maintain phenotype and neurotrophic factor secretion in vivo. Immunofluorescence sections of the gastrocnemius muscle obtained 10 days post-transplantation. Columns represent different transplanted groups (saline, naive, and differentiated hOMSC). First row illustrated staining for GFAP/VEGF/DAPI (A–C) and second row for HuNu/BDNF (D–F). Scale bars = 200 μm. Fluorescence emission analysis of GFAP, VEGF, and BDNF intensity (G–I). Abbreviations: BDNF, brain-derived neurotrophic factor; DAPI, 4’,6-diamidino-2-phenylindole; GFAP, glial fibrillary acidic protein; hOMSC, human oral mucosa stem cells; hOMSC-NS, human oral mucosa stem cells-neuronal support; HuNu, human nuclei; VEGF, vascular endothelial growth factor.
a high propensity to differentiate along glial linages and providing a neuronal support function similar to glial cells of the nervous system.

To conceive hOMSC-NS as a general neuroprotective strategy, a number of issues remain to be elucidated in further studies. (a) Cell survival at the graft site remains to be elucidated. (b) The behavior and fate of the transplanted cells for longer time periods remain to be addressed. (c) The mechanisms involved in the observed motor recovery and in the neuromuscular synaptic preservation remain to be elucidated. (d) hOMSC used in the present study were obtained from relatively young and healthy donors. Our preliminary results (data not shown) indicate that donor aging does not affect the basic properties of hOMSC such as proliferation and their capacity to differentiate in vitro. However, it is unknown whether aging or other inherited or acquired diseases of the donor affect their functionality in vivo. It also remains to be established whether hOMSC can be used for allogenic transplantation. (e) In the present study, hOMSC were tested in a model of injured but young animals. It remains to be established how the age of the host affects the function of hOMSC-NS in vivo.

**CONCLUSION**

Our findings show for the first time that astrocyte-like cells with enhanced neurotrophic factor secretion and neuroprotective abilities can be successfully obtained through hOMSC differentiation. Considering the many advantages of using oral mucosa stem cells and the results shown in this work, hOMSC emerge as a novel stem cell population for autologous cell therapy of peripheral nerve injuries and possibly other neuropathies.

**ACKNOWLEDGMENTS**

We thank Dr. Igor Tarasenko for assistance with the animal model and Veronica Silva for editorial assistance. This work was performed in partial fulfillment of the requirements for a degree of Javier Ganz, Sackler Faculty of Medicine, Tel Aviv University. This work was supported, in part, by Binational United States-Israel Science Foundation (Grant 2007049 to S. Pitaru.), Israel Science Foundation of the Israeli Academy of Science (Grant 646/09 to S. Pitaru), and Ministry of Immigrant Absorption and SAIA Doctoral Prize and Scholarship Fund for Research fellowship (to J.G.).
AUTHOR CONTRIBUTIONS

J.G.: conception and design, collection and/or assembly of data, data analysis and interpretation, manuscript writing, final approval of manuscript; I.A.: collection and/or assembly of data; T.B.-Z.: collection and/or assembly of data, data analysis and interpretation; M.D.-N.: data analysis and interpretation; S. Pour and S.A.: provision of study material or patients; S. Pitaru: conception and design, data analysis and interpretation, manuscript writing, financial support, final approval of manuscript; D.O.: conception and design, financial support, data analysis and interpretation, final approval of manuscript.

DISCLOSURE OF POTENTIAL CONFLICTS OF INTEREST

J.G. is an uncompensated patent holder. S. Pitaru is an uncompensated patent holder and compensated consultant with brainstorm cell therapeutics.

REFERENCES

1. Ganz J, Lev N, Melamed E et al. Cell replacement therapy for Parkinson’s disease: How close are we to the clinic? Expert Rev Neurother 2011;11:1325–1339.
2. Kimelberg HK, Nedergaard M. Functions of astrocytes and their potential as therapeutic targets. Neurotherapeutics 2010;7:338–353.
3. Yamakata K, Boillee S, Roberts EA et al. Mutant SOD1 in cell types other than motor neurons and oligodendrocytes accelerates onset of disease in ALS mice. Proc Natl Acad Sci USA 2008;105:7594–7599.
4. Barbeito LH, Pezar M, Cassina P et al. A role for astrocytes in motor neuron loss in amyotrophic lateral sclerosis. Brain Res Brain Res Rev 2004;47:263–274.
5. Miquel E, Cassina A, Martinez-Palma L et al. Modulation of astrocytic mitochondrial function by dichloroacetate improves survival and motor performance in inherited amyotrophic lateral sclerosis. PLoS One 2012;7:e34776.
6. Diaz-Amarilla P, Olivera-Bravo S, Trías E et al. Phenotypically aberrant astrocytes that promote motoneuron damage in a model of inherited amyotrophic lateral sclerosis. Proc Natl Acad Sci USA 2010;108:18126–18131.
7. Nakajima K, Hida H, Shimano Y et al. GDNF is a major component of trophic activity in DA-depleted striatum for survival and neurite extension of DAergic neurons. Brain Res 2001;916:76–84.
8. Bergløf E, Af Bjerkén S, Strömberg I. Glial influence on nerve fibre formation from rat ventral mesencephalic organotypic tissue cultures. J Comp Neurol 2007;501:431–442.
9. L’Episcopo F, Tirolo C, Testa N et al. Glia as a turning point in the therapeutic strategy of Parkinson’s disease. CNS Neurosurg Drug Targets 2010;9:349–372.
10. Faulkner JR, Herrmann JE, Woo MI et al. Reactive astrocytes protect tissue and preserve function after spinal cord injury. J Neurosci 2004;24:2143–2155.
11. Franklin RJ, Blakemore WF. Glial-cell transplantation and plasticity in the O-2A lineage—implications for CNS repair. Trends Neurosci 1995;18:151–156.
12. Lepore AC, Rauck B, Dejée C et al. Focal transplantation-based astrocyte replacement is neuroprotective in a model of motor neuron disease. Nat Neurosci 2008;11:1294–1301.
13. Sofroniew MV, Vinters HV. Astrocytes: Biology and pathology. Acta Neuropathol 2010;119:7–35.
14. Gritti A, Bonfanti L. Neuronal-glial interactions in central nervous system neurogenesis: The neural stem cell perspective. Neuron Glia Biol 2007;3:309–323.
15. Sadan O, Bahat-Stromza M, Barhum Y et al. Protective effects of neurotrophic factor-secreting cells in a 6-OHDA rat model of Parkinson disease. Stem Cells Dev 2009;18:1179–1190.
16. Sadan O, Melamed E, Offen D. Bone marrow-derived mesenchymal stem cell therapy for neurodegenerative diseases. Expert Opin Biol Ther 2009;9:1487–1497.
17. Sadan O, Shemesh N, Cohen Y et al. Adult neurotrophic factor-secreting stem cells: A potential novel therapy for neurodegenerative diseases. Isr Med Assoc J 2009;11:201–204.
18. Bahat-Stromza M, Barhum Y, Levy YS et al. Induction of adult human bone marrow mesenchymal stromal cells into functional astrocyte-like cells: Potential for restorative treatment in Parkinson’s disease. J Mol Neurosci 2009;39:199–210.
19. Dadon-Nachum M, Sadan O, Srogl I et al. Differentiated mesenchymal stem cells for sciatic nerve injury. Stem Cell Rev 2011;7:664–671.
20. Xiong N, Zhang Z, Huang J et al. VEGF-expressing human umbilical cord mesenchymal stem cells, an improved therapy strategy for Parkinson’s disease. Gene Ther 2011;18:394–402.
21. Kityanant N, Kityanant Y, Svendsen CN et al. BDNF-, IGF-1- and GDNF-secreting human neural progenitor cells rescue amyloid β-induced toxicity in cultured rat septal neurons. Neurochem Res 2012;37:143–152.
22. Ozdinler PH, Macklis JD. IGF-I specifically enhances axon outgrowth of corticospinal motor neurons. Nat Neurosci 2006;9:1371–1381.
23. Dobrowolny G, Giacinti C, Pelosi L et al. Muscle expression of a local IGF-1 isoform protects motor neurons in an ALS mouse model. J Cell Biol 2005;168:193–199.
24. Azzouz M, Ralph GS, Storkebaum E et al. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004;429:413–417.
25. Zheng C, Skold MK, Li J et al. VEGF reduces astrogliosis and preserves neuromuscular junctions in ALS transgenic mice. Biochem Biophys Res Commun 2007;363:989–993.
26. Accadi G, Angelouva RA, Yang H et al. Increased survival and function of SOD1 mice after glial cell-derived neurotrophic factor gene therapy. Hum Gene Ther 2002;13:1047–1059.
27. Mohajeri MH, Figlewicz DA, Bohn MC. In vivo delivery of human mesenchymal stem cells to the macular degeneration. STEM CELLS 2009;27:2126–2135.
28. Barhum Y, Gai-Castro S, Bahat-Stromza M et al. Intracerebroventricular transplantation of human mesenchymal stem cells induced to secrete neurotrophic factors attenuates clinical symptoms in a mouse model of multiple sclerosis. J Mol Neurosci 2010;41:129–137.
29. Fisher-Shoval Y, Barhum Y, Sadan O et al. Transplantation of placenta-derived mesenchymal stem cells in the EAE mouse model of MS. J Mol Neurosci 2012;48:176–184.
30. Sadan O, Shemesh N, Barzilay R et al. Mesenchymal stem cells induced to secrete neurotrophic factors attenuate quinolinic acid toxicity: A potential therapy for Huntington’s disease. Exp Neurol 2012;234:417–427.
31. Levkovitch-Verbin H, Sadan O, Vanderswijs L et al. Intravitreal injections of neurotrophic factors secreting mesenchymal stem cells are neuroprotective in rat eyes following optic nerve transection. Invest Ophthalmol Vis Sci 2010;51:6394–6400.
32. Marynka-Kalmani K, Treves S, Yafee M et al. The lamina propria of adult human oral mucosa harbors a novel stem cell population. STEM CELLS 2010;28:984–995.
33. Le Douarin N, Dulac C, Dupin E et al. Gial cell lineages in the neural crest. Glia 1991;4:175–184.
34. Le Douarin NM, Creuzet S, Couly G et al. Neural crest cell plasticity and its limits. Development 2004;131:4637–4650.
35. Dupin E, Real C, Glavieux-Pardanaud C et al. Reversal of developmental restrictions in neural crest lineages: Transition from Schwann cells to glial-melanocytic precursors in vitro. Proc Natl Acad Sci USA 2003;100:5229–5233.
36. Davies LC, Locke M, Webb RD et al. A multipotent neural crest-derived progenitor cell population is resident within the oral mucosa lamina propria. Stem Cells Dev 2010;19:819–830.
37. Durham HD, Dahrouge S, Cashman NR. Evaluation of the spinal cord neuron X neuroblastoma hybrid cell line NSC-34 as a model for neurotoxicity testing. Neurotoxicology 1993;14:387–395.
38. Mousavi K, Jasmin BJ. BDNF is expressed in skeletal muscle satellite cells and inhibits myogenic differentiation. J Neurosci 2006;26:5739–5749.
39. Clow C, Jasmin BJ. Brain-derived neurotrophic factor regulates satellite cell differentiation and skeletal muscle regeneration. Mol Biol Cell 2010;21:2182–2190.
40. Lu B, Malcuit C, Wang S et al. Long-term safety and function of RPE from human embryonic stem cells in preclinical models of macular degeneration. STEM CELLS 2009;27:2126–2135.
neurodegenerative and muscle degenerative diseases. Med Mol Morphol 2008;41:14–19.

45 Shimizu S, Kitada M, Ishikawa H et al. Peripheral nerve regeneration by the in vitro differentiated-human bone marrow stromal cells with Schwann cell property. Biochem Biophys Res Commun 2007;359:915–920.

46 Mohajeri M, Farazmand A, Mohyeddin Bonab M et al. FOXP3 gene expression in multiple sclerosis patients pre- and post mesenchymal stem cell therapy. Iran J Allergy Asthma Immunol 2011;10:155–161.

47 Dadon-Nachum MB-ZT, Srugo I, Shamir H M, Melamed E, Yaffe D, Offen D. Therapeutic effect of myogenic cells modified to express neurotrophic factors in a rat model of sciatic nerve injury. Journal of Stem Cells and Regenerative Medicine 2012;8:22–26.

48 Jin Y, Neuhuber B, Singh A et al. Transplantation of human glial restricted progenitors and derived astrocytes into a contusion model of spinal cord injury. J Neurotrauma 2011;28:579–594.

49 Lepore AC, O’Donnell J, Kim AS et al. Human glial-restricted progenitor transplantation into cervical spinal cord of the SOD1 mouse model of ALS. PLoS One 2011;6:e25968.

50 Dadon-Nachum M, Melamed E, Offen D. Stem cells treatment for sciatric nerve injury. Expert Opin Biol Ther 2011;11:1591–1597.

51 Stenderup K, Justesen J, Clausen C et al. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone 2003;33:919–926.

52 Zhou S, Greenberger JS, Eppefly MW et al. Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts. Aging Cell 2008;7:335–343.

53 Stoltzing A, Jones E, McGonagle D et al. Age-related changes in human bone marrow-derived mesenchymal stem cells: Consequences for cell therapies. Mech Ageing Dev 2008;129:163–173.

54 Dupin E, Glavieux C, Vaigot P et al. Endothelin 3 induces the reversion of melanocytes to glia through a neural crest-derived glial-melanocytic progenitor. Proc Natl Acad Sci USA 2000;97:7882–7887.

55 Pinkas-Kramarski R, Eilam R, Spiegler O et al. Brain neurons and glial cells express Neu differentiation factor/herégulin: A survival factor for astrocytes. Proc Natl Acad Sci USA 1994;91:9387–9391.

56 Kerber G, Streif R, Schweiger FW et al. Neuregulin-1 isoforms are differentially expressed in the intact and regenerating adult rat nervous system. J Mol Neurosci 2003;21:149–165.

57 Adachi T, Takanaga H, Kunimoto M et al. Influence of LIF and BMP-2 on differentiation and development of glial cells in primary cultures of embryonic rat cerebral hemisphere. J Neurosci Res 2005;79:608–615.

58 Kang K, Song MR. Diverse FGF receptor signaling controls astrocyte specification and proliferation. Biochem Biophys Res Commun 2010;395:324–329.

59 Qian X, Davis AA, Goderie SK et al. FGF2 concentration regulates the generation of neurons and glia from multipotent cortical stem cells. Neuron 1997;18:81–93.

60 Song MR, Ghosh A. FGF2-induced chondromin remodelung regulates CNTF-mediated gene expression and astrocyte differentiation. Nat Neurosci 2004;7:229–235.

61 Ravin R, Hoeppner DJ, Munno DM et al. Potency and fate specification in CNS stem cell populations in vitro. Cell Stem Cell 2008;3:670–680.

62 Raballo R, Rhee J, Lyn-Cook R et al. Basic fibroblast growth factor (Bfgf) is necessary for cell proliferation and neurogenesis in the developing cerebral cortex. J Neurosci 2000;20:5012–5023.

63 Vaccarino FM, Schwartz ML, Raballo R et al. Changes in cerebral cortex size are governed by fibroblast growth factor during embryogenesis. Nat Neurosci 1999;2:848.

64 Stanimirovic DB, Ball R, Small DL et al. Developmental regulation of glutamate transporters and glutamine synthetase activity in astrocyte cultures differentiated in vitro. Int J Dev Neurosci 1999;17:173–184.

65 Bayatti N, Engele J. Cyclic AMP differential regulates the expression of fibroblast growth factor and epidermal growth factor receptors in cultured cortical astroglia. Neuroscience 2002;114:81–89.

66 Condorelli DF, Dell’Albani P, Mudo G et al. Expression of neurotrophins and their receptors in primary astroglial cultures: Induction by cyclic AMP-elevating agents. J Neurochem 1994;63:509–516.